Immunomodulatory treatments and cognition in MS

Mückschel, Moritz; Beste, Christian; Ziemssen, Tjalf

doi:10.1111/ane.12656

Cited by 16 publications

(12 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cognitive impairment was significant only at disease duration greater than five years suggesting the existence of an early therapeutic window [5]. However, the effects of disease modifying drugs (DMD) on cognitive impairments in MS have not been thoroughly studied [6], though several DMD have demonstrated a beneficial effect on cognitive performance [7] and spared brain atrophy [8–10], thus showing the potential to decrease cognitive decline.…”

Section: Introductionmentioning

confidence: 99%

Cognitive function in multiple sclerosis: A long-term look on the bright side

et al. 2019

View full text Add to dashboard Cite

Background Multiple sclerosis (MS) may lead to cognitive decline over-time. Objectives Characterize cognitive performance in MS patients with long disease duration treated with disease modifying drugs (DMD) in relation to disability and determine the prevalence of cognitive resilience. Methods Cognitive and functional outcomes were assessed in 1010 DMD-treated MS patients at least 10 years from onset. Cognitive performance was categorized as high, moderate or low, and neurological disability was classified according to the Expanded Disability Status Scale (EDSS) as mild, moderate or severe. Relationship between cognitive performance and disability was examined. Results After a mean disease duration of 19.6 (SD = 7.7) years, low cognitive performance was observed in 23.7% (N = 239), moderate performance in 42.7% (N = 431), and 33.7% (N = 340) had high cognitive performance, meeting the definition of cognitively resilient patients. Within the group of patients with low cognitive performance, severe disability was observed in 50.6% (121/239), while in the group of patients with high cognitive performance, mild disability was observed in 64.4% (219/340). Differences between the group of patients with high cognitive performance and severe disability (4.5%) and the group of patients with low cognitive performance and mild disability (5.0%) were not accounted for by DMD treatment duration. Conclusions The majority of DMD treated MS patients did not have cognitive decline that could impair their quality of life after disease of extended duration.

show abstract

Section: Introductionmentioning

confidence: 99%

Cognitive function in multiple sclerosis: A long-term look on the bright side

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Therefore, the proliferation of computerized neuropsychological assessment devices (CNADs) for screening and monitoring cognitive impairment is increasing exponentially [53]. This can support the general strategy to provide personalized MS management in which the assessment of cognitive functions using digital approaches needs to be implemented alongside immunological, genetic and MRI profiling of the individual patient [6,54].…”

Section: Discussionmentioning

confidence: 99%

On the Reliability of Examining Dual-Tasking Abilities Using a Novel E-Health Device—A Proof of Concept Study in Multiple Sclerosis

Böttrich

Mückschel

Dillenseger

et al. 2020

JCM

View full text Add to dashboard Cite

The assessment of neuropsychological functions and especially dual-tasking abilities is considered to be increasingly relevant in the assessment of neurological disease, and Multiple Sclerosis (MS) in particular. However, the assessment of dual-tasking abilities is hindered by specific software requirements and extensive testing times. We designed a novel e-health (progressive web application-based) device for the assessment of dual-tasking abilities usable in “bedside” and outpatient clinic settings and examined its reliability in a sample of N = 184 MS patients in an outpatient setting. Moreover, we examined the relevance of dual-tasking assessment using this device with respect to clinically relevant parameters in MS. We show that a meaningful assessment of dual-tasking is possible within 6 min and that the behavioral readouts overall show good reliability depending on dual-tasking difficulty. We show that dual-tasking readouts were correlated with clinically relevant parameters (e.g., EDSS, disease duration, processing speed) and were not affected by fatigue levels. We consider the tested dual-tasking assessment device suitable for routine clinical neuropsychological assessments of dual-tasking abilities. Future studies may further evaluate this test regarding its suitability in the long-term follow up assessments and to assess dual-tasking abilities in other neurological and psychiatric disorders.

show abstract

“…So, the proliferation of computerized neuropsychological assessment devices (CNADs) for screening and monitoring cognitive impairment is increasing exponentially (47). This can support the general strategy to provide personalized MS management in which the assessment of cognitive functions using digital approaches needs to be implemented alongside immunological, genetic and MRI profiling of the individual patient (5,48).…”

Section: Discussionmentioning

confidence: 99%

On the reliability of examining dual-tasking abilities using a novel e-Health device – a proof of concept study in Multiple Sclerosis

Böttrich¹,

Mückschel²,

Dillenseger³

et al. 2020

Preprint

View full text Add to dashboard Cite

The assessment of neuropsychological functions and especially dual-tasking abilities is considered to be increasingly relevant in the assessment of neurological disease and Multiple Sclerosis (MS) in particular. Yet, the assessment of dual-tasking abilities is hindered by specific software requirements and extensive testing times. We designed a novel e-health (progressive web application-based) device for the assessment of dual-tasking abilities usable in “bedside” and outpatient clinic settings and examined its reliability in a sample of N=184 MS patients in an outpatient setting. Moreover, we examined the relevance of dual-tasking assessment using this device with respect to clinically relevant parameters in MS. We show that a meaningful assessment of dual-tasking is possible within 6 minutes and that reliabilities of the behavioral readouts ranged between .81 to .92 depending on dual-tasking difficulty. We show that dual-tasking readouts were correlated with clinically relevant parameters (e.g. EDSS, disease duration, processing speed) and were not affected by fatigue levels. We consider the tested dual-tasking assessment device suitable for routine clinical neuropsychological assessments of dual-tasking abilities. Future studies may further evaluate this test regarding its suitability in the long-term follow up assessments and to assess dual-tasking abilities in other neurological and psychiatric disorders.

show abstract

Immunomodulatory treatments and cognition in MS

Cited by 16 publications

References 55 publications

Cognitive function in multiple sclerosis: A long-term look on the bright side

Cognitive function in multiple sclerosis: A long-term look on the bright side

On the Reliability of Examining Dual-Tasking Abilities Using a Novel E-Health Device—A Proof of Concept Study in Multiple Sclerosis

On the reliability of examining dual-tasking abilities using a novel e-Health device – a proof of concept study in Multiple Sclerosis

Contact Info

Product

Resources

About